Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029

ملخص مفصل

Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and…

Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company has multiple paths to its $6 billion revenue target for 2029, citing growth in its Signatera cancer testing business and opportunities to improve reimbursement.

Speaking at a UBS event, Brophy also addressed Natera's CEO transition, plans for colorectal cancer screening and preparations to launch Signatera in Japan. He described the 2029 target as achievable without relying heavily on businesses that do not yet generate revenue.

Brophy said the transition from outgoing CEO Steve to Solomon would bring substantial continuity. Solomon joined Natera in 2011 and played a central role in developing its Prospera organ health business and Signatera, including decisions on clinical trials, product strategy and the commercial rollout, Brophy said.

Asked why the transition appeared abrupt, Brophy said Solomon was already deeply involved in the company's important decisions and meetings. A lengthy overlap could have created uncertainty about who was in charge, he said, adding that Steve remains available under a transition agreement.

Brophy also said Natera's commercial capabilities extend beyond any one executive, pointing to its experienced sales leadership and established processes.

On the 2029 revenue target, Brophy said Natera is crossing $3 billion in revenue and aims to double that figure. He said the company does not need to reach all its existing long-term goals to hit $6 billion.

For Signatera, Brophy cited an indicative average selling price of $1,450 in 2029, compared with approximately $1,290 currently. He said the company's longer-term ambition is to reach $2,000, but described the lower figure as achievable through additional Medicare coverage and progress with other reimbursement. Natera also needs repeat testing among existing patients and sustainable growth in new patients, he said.

Brophy said the market for minimal residual disease, or MRD, testing remains in its early stages.

The business…

مطلع المقال، مقتطف من Yahoo Finance. لقراءة المقال كاملًا، افتحه على موقع الناشر.